54 results about "Enzyme immunoassay method" patented technology

The invention provides a method for preparing acrylamide complete antigen. The method is as follows: amine uncoupling reaction is directly carried out between N-acryloyloxy succinimide and the surface amino group of carrier protein molecule in a neutral or weakly alkaline phosphate buffer solution, thereby forming acrylamide complete antigen. Polyclonal antibody capable of realizing specificity identification of acrylamide is obtained through a complete antigen immune animal, so as to establish an enzyme immunoassay method suitable for measuring the content of acrylamide in an aqueous solution or food and to provide a corresponding reagent box. The method has simple operation and does not need other reaction reagent, thereby furthest maintaining the structural integrity of acrylamide; moreover, the method ensures that a coupling position is at a maximum distance from a feature group so as to fully expose the feature structure of acrylamide molecule. The established enzyme immunoassay method of acrylamide and the reagent box have strong specificity, high sensitivity and convenient operation, and are suitable to realize massive sample detection which has low cost and is quick and simple.

A chemiluminescent enzyme immunoassay method whereby a target substance such as a protein is assayed. This chemiluminescent enzyme immunoassay method comprises: the step of capturing an immune complex containing an enzyme-labeled antibody, which is labeled with an enzyme acting a chemiluminescent substrate, and the target substance on a support having no solution layer; the step of overlaying a support membrane containing the chemiluminescent substrate on the immune complex having been captured above; and the step of measuring the luminescence dose caused by the reaction between the enzyme-labeled antibody and the chemiluminescent substrate to thereby quantify the target substance. Since a highly sensitive chemiluminescent enzyme immunoassay is conducted by using a non-liquid phase type reaction system in the chemiluminescent enzyme immunoassay method as described above, multiple items can be assayed by using only a small amount of a specimen and, furthermore, the target substance can be assayed at a high sensitivity thereby without resorting to any troublesome procedures such as pipetting a reagent.

Enzyme immunoassay method for detecting Kebaiwei includes (1) synthesizing half antigen and artificial antigen; (2) preparing polyclonal antibody, monoclonal antibody, or gene engineering antibody of possessing specificity to Kebaiwei; (3) preparing enzyme labeled antigen; (4) using second antibody to coat enzyme labeled plate and close the plate to save Kebaiwei; reaction is carried out between anti Kebaiwei antibody and second antibody and fixed on the enzyme labeled plate; (5) washing out free object, adding sample to be tested, and enzyme labeled antigen or Kebaiwei labeled sample, and enzyme labeled antigen; (6) washing out free object, adding substrate of enzyme and developer. Intensity of enzyme promoting color reaction is proportional to quantity of enzyme labeled antigen bound on antibody, and is inversely proportional to content of Kebaiwei in sample. Features are: long term storage, increasing sensitivity, accuracy, simple and quick test operation.

The present invention discloses a gold-immunochromatography assay method which is used for detecting the aquatic product food allergy. The method comprises preparing colloidal gold, labeling protein with the colloidal gold, detecting with the gold-immunochromatography assay, and other steps. The invention adopts the gold-immunochromatography assay technology to detect the aquatic product food allergy; the technology not only has the advantages of high specificity and high sensitivity of the enzyme immunoassay, but also has the advantages of rapid and simple detection of the prick test; and the technology can rapidly detect whether the food has aquatic product allergens or aquatic product allergen antibodies.

The invention discloses a direct competitive enzyme immunoassay method based on a nano-gold plasma excimer, and immunoassay visible detection on small-molecule compounds can be realized. The direct competitive enzyme immunoassay method comprises the steps of competitively combining a test sample possibly containing the small-molecule compounds and haptens labeled with catalase with small-molecule compound antibodies covering a solid phase, decomposing hydrogen peroxide through the combined enzyme-labeled antigens, reducing chloroauric acid into nano-gold through the hydrogen peroxide under a certain buffering condition, and detecting the small-molecule compounds in the sample by observing the color or the light absorption intensity of a developing liquid. The method disclosed by the invention has the advantages of high sensitivity, simplicity in operation, low cost, visible result distinguishing and the like, and the shortcomings of the conventional small-molecule compound enzyme-linked immunoassay detection technology are overcome.

A detection method includes using PAT protein as antigen to immunize animal for obtaining specific poly antibody, cross - linking the antibody on agarose gel to prepare immuiaffinity chromatographic column, using affinity column to enrich PAT protein after detected sample is processed, collecting affinity column eluent and carrying out enzyme - linked immunosorbant assay for confirming PAT protein content in it. The kit of the method is also disclosed.

A method for testing trace Bt toxic protein in the bodies of insects in a transgenic Bt crop habitat includes the following steps: in the first step, collecting insects to be tested growing in a transgenic Bt crop field, and preparing insect liquid to be tested; in the second step, collecting insects growing on non-transgenic Bt plants in a lab, which belong to the same species or variety as the insects to be tested, and preparing contrast insect liquid; in the third step, using the contrast insect liquid to prepare standard Bt toxic proteins with a series of concentrations; in the fourth step, utilizing an enzyme immunoassay method to determine the optical density values of the standard Bt toxic proteins and the insect liquid to be tested at the wavelength of 650 nanometers; in the fifth step, obtaining a standard equation according to the concentrations of the standard Bt toxic proteins and the corresponding optical density values, and calculating the Bt toxic protein concentration in the insect liquid to be tested according to the standard equation. The test method has extremely high sensitivity and good repeatability.

[PROBLEMS] To confirm the presence of a solubilized human IL-18 receptor-α by a novel ELISA method and provide an assay kit and a medicinal composition containing the solubilized human IL-18 receptor-α as the active ingredient. [MEANS FOR SOLVING PROBLEMS] A solubilized human interleukin-18 receptor-α, a method of assaying the solubilized human interleukin-18 receptor-α by an enzyme immunoassay method characterized by using the following antibody (A), a kit for assaying the solubilized human interleukin-18 receptor-α and a medicinal composition containing the solubilized human IL-18 receptor-α. (A) An anti-human interleukin-18 receptor-α monoclonal antibody capable of recognizing the same epitope as an H44 mouse anti-human interleukin-18 receptor-α monoclonal antibody.

The invention discloses a novel ivermectin hapten. The novel ivermectin hapten is obtained through reacting with carboxymethoxylamine hemihydrochloride at the C4-OH position of ivermectin and substituting hydroxyl on C4 with carboxymethyl hydroxyamino; the derivative is coupled with carrier protein to be used as an immunogen, and can be used for preparing a monoclonal antibody for resisting an abamectin type drug. The invention further discloses one broad-spectrum monoclonal antibody for resisting the abamectin type drug; the monoclonal antibody can be used for simultaneously and specificallyidentifying abamectin, ivermectin, eprinomectin and emamectin; and an enzyme immunoassay method and a kit, which are established by utilizing the monoclonal antibody are suitable for detecting residues of the abamectin type drug in animal tissues and have the advantages of sensitivity in detection, high accuracy, good precision and the like.

The invention relates to the technical field of in vitro diagnosis and detection, in particular to an application of a thionicotinamide adenine dinucleotide I to a homogeneous enzyme immunodiagnosticreagent. The diagnostic reagent is a glycocholic acid detection reagent and a CMPF reagent. The defect of relatively poor accuracy and repeatability of a detection result caused by relatively poor stability of the glycocholic acid reagent and the CMPF reagent in the prior art is overcome; a nicotinamide adenine dinucleotide II in the homogeneous enzyme immunodiagnostic reagent for homogeneous enzyme immunoassay is replaced with the thionicotinamide adenine dinucleotide I, so that the problem of relatively poor stability of the homogeneous enzyme immunodiagnostic reagent is effectively solved,the repeatability of the detection result of the reagent is improved, and the accuracy of the detection result is improved; and meanwhile, the anti-hemoglobin interference resistance of the reagent isimproved, the influence of a hemolysis phenomenon of a clinical sample on the detection result is weakened, and the detectability of the homogeneous enzyme immunodiagnostic reagent is improved, so that the test reagent is suitable for a conventional microplate reader, the detection cost is effectively reduced, and meanwhile, the usage amount of the reagent and raw materials is reduced.

The invention discloses a heparin-binding protein assay kit applying a magnetic particle chemiluminescence enzyme immunoassay method. The heparin-binding protein assay kit comprises avidin-labeled magnetic particles, a biotin-labeled HBP antibody 1, a horseradish peroxidase-labeled HBP antibody 2, an HBP calibrator, a concentrated washing liquid and a substrate. The invention also discloses a preparation method and a determination method of the kit. The novel immunoassay kit disclosed by the invention is used for quantitatively assaying HBP in human body fluid in vitro, overcomes personal errors of a traditional enzyme immunoassay (EIA) method in the aspect of operation, can quantitatively and objectively reflect the existence of HBP, and provides a more powerful experimental diagnosis basis for clinical diagnosis, curative effect observation and prognosis judgment. The heparin binding protein determination method provided by the invention is high in specificity, good in repeatability,high in detection sensitivity, wide in linear range, high in automation degree and simple, convenient and rapid to operate; compared with an EIA method, the method has the advantages of rapidness, simplicity, convenience, accuracy and small interference.